WO2001064751A3 - High potency recombinant antibodies and method for producing them - Google Patents

High potency recombinant antibodies and method for producing them Download PDF

Info

Publication number
WO2001064751A3
WO2001064751A3 PCT/US2001/006815 US0106815W WO0164751A3 WO 2001064751 A3 WO2001064751 A3 WO 2001064751A3 US 0106815 W US0106815 W US 0106815W WO 0164751 A3 WO0164751 A3 WO 0164751A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
neutralizing
high potency
disclosed
producing
Prior art date
Application number
PCT/US2001/006815
Other languages
French (fr)
Other versions
WO2001064751A2 (en
Inventor
James F Young
Scott Koenig
Leslie S Johnson
William D Huse
Herren Wu
Jeffry D Watkins
Original Assignee
Medimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2001564244A priority Critical patent/JP2003525061A/en
Application filed by Medimmune Inc filed Critical Medimmune Inc
Priority to DK01914657.0T priority patent/DK1259547T3/en
Priority to EP01914657A priority patent/EP1259547B1/en
Priority to CA002401652A priority patent/CA2401652A1/en
Priority to AU2001240020A priority patent/AU2001240020B9/en
Priority to ES01914657T priority patent/ES2390761T3/en
Priority to AU4002001A priority patent/AU4002001A/en
Publication of WO2001064751A2 publication Critical patent/WO2001064751A2/en
Publication of WO2001064751A3 publication Critical patent/WO2001064751A3/en
Priority to AU2006203134A priority patent/AU2006203134B2/en
Priority to AU2007202040A priority patent/AU2007202040B2/en
Priority to AU2010202006A priority patent/AU2010202006B2/en
Priority to AU2010219289A priority patent/AU2010219289B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Abstract

High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for production high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.
PCT/US2001/006815 2000-01-27 2001-03-01 High potency recombinant antibodies and method for producing them WO2001064751A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ES01914657T ES2390761T3 (en) 2000-03-01 2001-03-01 Recombinant high-potency antibodies and method for their production
DK01914657.0T DK1259547T3 (en) 2000-03-01 2001-03-01 HIGH POTENTIAL, RECOMBINANT ANTIBODIES AND PROCEDURE FOR PRODUCING THEM
EP01914657A EP1259547B1 (en) 2000-03-01 2001-03-01 High potency recombinant antibodies and method for producing them
CA002401652A CA2401652A1 (en) 2000-03-01 2001-03-01 High potency recombinant antibodies and method for producing them
AU2001240020A AU2001240020B9 (en) 2000-03-01 2001-03-01 High potency recombinant antibodies and method for producing them
JP2001564244A JP2003525061A (en) 2000-03-01 2001-03-01 High potency recombinant antibody and method for producing the same
AU4002001A AU4002001A (en) 2000-03-01 2001-03-01 High potency recombinant antibodies and method for producing them
AU2006203134A AU2006203134B2 (en) 2000-01-27 2006-07-21 Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2007202040A AU2007202040B2 (en) 2000-03-01 2007-05-08 High potency recombinant antibodies and method for producing them
AU2010202006A AU2010202006B2 (en) 2000-01-27 2010-05-18 Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2010219289A AU2010219289B2 (en) 2000-03-01 2010-09-03 High potency recombinant antibodies and method for producing them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18625200P 2000-03-01 2000-03-01
US60/186,252 2000-03-01

Publications (2)

Publication Number Publication Date
WO2001064751A2 WO2001064751A2 (en) 2001-09-07
WO2001064751A3 true WO2001064751A3 (en) 2001-12-20

Family

ID=22684221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006815 WO2001064751A2 (en) 2000-01-27 2001-03-01 High potency recombinant antibodies and method for producing them

Country Status (10)

Country Link
US (2) US7700735B2 (en)
EP (3) EP1259547B1 (en)
JP (2) JP2003525061A (en)
AU (4) AU4002001A (en)
CA (1) CA2401652A1 (en)
CY (1) CY1113298T1 (en)
DK (1) DK1259547T3 (en)
ES (1) ES2390761T3 (en)
PT (1) PT1259547E (en)
WO (1) WO2001064751A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986686B2 (en) 2002-06-14 2015-03-24 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US9283274B2 (en) 2009-10-06 2016-03-15 Medimmune Limited RSV specific binding molecule

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656467B2 (en) * 2000-01-27 2003-12-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
CA2401652A1 (en) 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them
EP2338512A1 (en) * 2000-11-28 2011-06-29 MedImmune, LLC Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
PT1355919E (en) 2000-12-12 2011-03-02 Medimmune Llc Molecules with extended half-lives, compositions and uses thereof
AU2002365925A1 (en) * 2001-11-02 2003-09-02 Centocor Rsv proteins, antibodies, compositions, methods and uses
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
DE60329489D1 (en) * 2002-02-13 2009-11-12 Ludwig Inst Cancer Res FUSION PROTEINS HUMANIZED G250-SPECIFIC ANTIBODY AND USES THEREOF
ATE530577T1 (en) * 2002-05-10 2011-11-15 Purdue Research Foundation EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF APPLICATION THEREOF
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
ATE525398T1 (en) * 2002-05-10 2011-10-15 Medimmune Inc EPHA2 MONOCLONAL ANTIBODIES AND THEIR APPLICATION METHOD
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
JP2005533861A (en) * 2002-07-25 2005-11-10 メデュームン，インコーポレーテッド Therapies and prophylaxis of RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
AU2004207741B2 (en) 2003-01-24 2011-02-10 Applied Molecular Evolution, Inc Human IL-1 beta antagonists
JP2006523240A (en) * 2003-04-11 2006-10-12 メディミューン，インコーポレーテッド EphA2, hypoproliferative cell injury and epithelial and endothelial reconstitution
EP1617864A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc Epha2 and non-neoplastic hyperproliferative cell disorders
US7070786B2 (en) 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
WO2005079479A2 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US20090202986A1 (en) * 2004-10-22 2009-08-13 Huse William D Methods of optimizing antibody variable region binding affinity
AU2005302453A1 (en) * 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
WO2008070042A2 (en) * 2006-12-04 2008-06-12 Medimmune, Inc. High potency recombinant antibodies, methods for producing them and use in cancer therapy
CA2678628A1 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2173378B1 (en) 2007-06-27 2014-03-19 Admune Therapeutics LLC Complexes of il-15 and il-15ralpha and uses thereof
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
US8775090B2 (en) 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
EP2501722A4 (en) * 2009-11-19 2013-05-01 Univ Singapore Method for producing t cell receptor-like monoclonal antibodies and uses thereof
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
CN107011443B (en) 2011-05-04 2021-04-30 奥默罗斯公司 Compositions for inhibiting MASP-2 dependent complement activation
US9708393B2 (en) 2011-05-20 2017-07-18 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
CA2836799C (en) 2011-05-20 2021-05-18 Alderbio Holdings Llc Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
EP3662932B1 (en) 2011-05-20 2021-04-07 H. Lundbeck A/S Anti-cgrp compositions and use thereof
TWI659968B (en) 2013-03-14 2019-05-21 再生元醫藥公司 Human antibodies to respiratory syncytial virus f protein and methods of use thereof
DK3387019T3 (en) * 2015-12-09 2022-01-10 Scripps Research Inst RELAXIN-IMMUNOGLOBULIN INFUSION PROTEINS AND METHODS OF USE
EP3529272A2 (en) 2016-10-21 2019-08-28 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use
CA3040886A1 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
CA3040893A1 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005229A1 (en) * 1994-08-15 1996-02-22 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
EP0699756A1 (en) * 1994-08-04 1996-03-06 Bristol-Myers Squibb Company Novel mutant BR96 antibodies and functional equivalents reactive with human carcinomas
US5667988A (en) * 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
WO1998033919A2 (en) * 1997-01-30 1998-08-06 Ixsys, Incorporated Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517304A (en) 1980-07-01 1985-05-14 National Research Development Corporation Production of viral antigens
DE3235924T1 (en) 1981-03-06 1983-05-05 Celltech Ltd., Slough, Berkshire MONOCLONAL ANTIBODY
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US5340926A (en) 1983-03-25 1994-08-23 Celltech, Limited Process for the recovery of recombinantly produced protein from insoluble aggregate
JPS60100516A (en) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US5332805A (en) 1984-02-03 1994-07-26 Celltech Limited Process for the recovery of recombinantly produced chymosin from insoluble aggregate
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
FR2590674B1 (en) 1985-11-25 1989-03-03 Inst Nat Sante Rech Med NEW DIAGNOSTIC REAGENTS
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4659563A (en) 1986-01-27 1987-04-21 Miles Laboratories, Inc. High titer anti-respiratory syncytial virus intravenous immune globulin
US4717766A (en) 1986-01-27 1988-01-05 Miles Laboratories, Inc. Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin
US5271927A (en) 1986-02-13 1993-12-21 Celltech Limited Antibody conjugates with macrocyclic ligands
US5468606A (en) 1989-09-18 1995-11-21 Biostar, Inc. Devices for detection of an analyte based upon light interference
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
US4800078A (en) 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
GB8719041D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US4916893A (en) * 1987-09-02 1990-04-17 Sundstrand Corporation Multipurpose auxiliary power unit
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223254A (en) 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
AU617739B2 (en) 1987-12-23 1991-12-05 Pharmacia & Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
US5183657A (en) 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
JPH01268646A (en) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd Antitumor agent
US5137804A (en) 1988-05-10 1992-08-11 E. I. Du Pont De Nemours And Company Assay device and immunoassay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5354554A (en) 1989-02-10 1994-10-11 Celltech Limited Crosslinked antibodies and processes for their preparation
US6093872A (en) 1989-05-05 2000-07-25 Systemix, Inc. Extended human hematopoiesis in a heterologous host
FR2650598B1 (en) 1989-08-03 1994-06-03 Rhone Poulenc Sante DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5518725A (en) 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
WO1991006287A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5279935A (en) 1990-03-01 1994-01-18 Becton, Dickinson And Company Method of immunossay including deactivation of endogenous alkaline phosphatase
DE69120890T2 (en) 1990-05-03 1997-02-20 Systemix Inc HUMAN LYMPH TISSUE IN A HOST WITH ATTACKED IMMUNE SYSTEM
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
IE921169A1 (en) * 1991-04-10 1992-10-21 Scripps Research Inst Heterodimeric receptor libraries using phagemids
CA2108259C (en) 1991-04-22 2003-12-09 George R. Siber Process of screening plasma samples for effective antibody titers against respiratory viruses
EP0583356B1 (en) 1991-05-01 2002-07-31 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
CA2044940A1 (en) 1991-06-10 1992-12-11 Inder M. Verma Transdominant negative proto-oncogene
US5240694A (en) 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
US5418136A (en) 1991-10-01 1995-05-23 Biostar, Inc. Devices for detection of an analyte based upon light interference
EP0614530B1 (en) * 1991-11-15 1998-03-04 Cornell Research Foundation, Inc. Indirect immunoassay for dioxinlike compounds
US20020102257A1 (en) 1998-09-21 2002-08-01 Leslie Sid Johnson Human-murine chimeric antibodies against respiratory syncytial virus
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
AU686113B2 (en) 1992-09-16 1998-02-05 Scripps Research Institute, The Human neutralizing monoclonal antibodies to respiratory syncytial virus
US6685942B1 (en) 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
CA2153661A1 (en) 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5424189A (en) 1993-03-05 1995-06-13 Kansas State University Research Foundation Bovine respiratory syncytial virus detection and primers
NZ269735A (en) 1993-07-30 1998-01-26 Oravax Inc Monoclonal iga antibody against respiratory syncytial virus (rsv)
US5506209A (en) 1994-05-26 1996-04-09 Abbott Laboratories Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5538952A (en) 1994-05-26 1996-07-23 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
CA2230116A1 (en) 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
WO1997032572A2 (en) 1996-03-04 1997-09-12 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
FR2758331B1 (en) 1997-01-14 1999-03-05 Univ Bourgogne NEW MEANS FOR DIAGNOSIS, PREVENTION AND TREATMENT FOR CONTAMINATION OR INFECTIONS WITH MUCOUS TROPISM VIRUSES
US6117980A (en) 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6656467B2 (en) * 2000-01-27 2003-12-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20010034062A1 (en) 2000-02-09 2001-10-25 Scott Koenig Antibody gene therapy with adeno-associated viral vectors
CA2401652A1 (en) 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them
AU2001241918A1 (en) 2000-03-02 2001-09-12 Med Immune, Inc. Methods of enhancing activity of vaccines and vaccine compositions
EP2264072A1 (en) 2000-04-13 2010-12-22 The Rockefeller University Enhancement of antibody-mediated cytotoxicity.
CA2407292A1 (en) 2000-05-03 2001-11-08 Medimmune, Inc. Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
WO2001082965A1 (en) 2000-05-03 2001-11-08 Medimmune, Inc. Combination therapy of respiratory diseases using antibodies
EP1152199B1 (en) 2000-05-03 2005-07-27 IPV Inheidener Produktions- und Vertriebsgesellschaft mbH Thermal container
US20020018780A1 (en) 2000-05-25 2002-02-14 Scott Koenig Epitope-based vaccine for respiratory syncytial virus F-protein
WO2002011753A1 (en) 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
EP2338512A1 (en) 2000-11-28 2011-06-29 MedImmune, LLC Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
PT1355919E (en) 2000-12-12 2011-03-02 Medimmune Llc Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2005286770A1 (en) 2004-09-21 2006-03-30 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
AU2005302453A1 (en) 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667988A (en) * 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
EP0699756A1 (en) * 1994-08-04 1996-03-06 Bristol-Myers Squibb Company Novel mutant BR96 antibodies and functional equivalents reactive with human carcinomas
WO1996005229A1 (en) * 1994-08-15 1996-02-22 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
WO1998033919A2 (en) * 1997-01-30 1998-08-06 Ixsys, Incorporated Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEFTA L J F ET AL: "Kinetic and affinity constants of epitope specific anti-carcinoembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain constructs", IMMUNOTECHNOLOGY,NL,ELSEVIER SCIENCE PUBLISHERS BV, vol. 4, no. 1, 1 June 1998 (1998-06-01), pages 49 - 57, XP004127386, ISSN: 1380-2933 *
WU H ET AL: "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues", JOURNAL OF MOLECULAR BIOLOGY,LONDON,GB, vol. 294, no. 1, 19 November 1999 (1999-11-19), pages 151 - 162, XP000978702, ISSN: 0022-2836 *
YANG W -P ET AL: "CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range", JOURNAL OF MOLECULAR BIOLOGY,GB,LONDON, vol. 254, 1995, pages 392 - 403, XP000199739, ISSN: 0022-2836 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986686B2 (en) 2002-06-14 2015-03-24 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US9272032B2 (en) 2002-06-14 2016-03-01 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US9283274B2 (en) 2009-10-06 2016-03-15 Medimmune Limited RSV specific binding molecule

Also Published As

Publication number Publication date
EP1259547B1 (en) 2012-07-11
AU4002001A (en) 2001-09-12
EP2341075A1 (en) 2011-07-06
AU2007202040B2 (en) 2010-06-10
CA2401652A1 (en) 2001-09-07
US8153133B2 (en) 2012-04-10
ES2390761T3 (en) 2012-11-16
DK1259547T3 (en) 2012-10-15
PT1259547E (en) 2012-10-15
AU2010219289B2 (en) 2012-05-10
EP2341074A1 (en) 2011-07-06
WO2001064751A2 (en) 2001-09-07
AU2010219289A1 (en) 2010-09-30
JP2003525061A (en) 2003-08-26
EP1259547A2 (en) 2002-11-27
AU2001240020B2 (en) 2007-02-08
US7700735B2 (en) 2010-04-20
US20100239574A1 (en) 2010-09-23
AU2007202040A1 (en) 2007-05-24
JP2010162025A (en) 2010-07-29
US20020098189A1 (en) 2002-07-25
AU2001240020B9 (en) 2008-12-04
CY1113298T1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
WO2001064751A3 (en) High potency recombinant antibodies and method for producing them
ATE402192T1 (en) ANTI-CCR4 ANTIBODIES AND FRAGMENTS THEREOF
PL343245A1 (en) Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
WO2001034801A3 (en) Recombinant gelatin in vaccines
WO2000076540A3 (en) Streptococcus pneumoniae proteins and vaccines
IL128014A (en) Method of producing active immunity with vaccine conjugate, a vaccine preparation useful for the production of said vaccine conjugate and a process for the manufacture of said vaccine
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
WO2002024887A3 (en) Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
WO2005061537A3 (en) Squamous cell carcinoma antigens and use thereof
WO2002044366A3 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
HU9300349D0 (en) Method for producing dibenzo- or benzo-pyrido-cyclohepta-piperidine derivatives or piperidylidene or piperazine derivatives thereof as well as pharmaceutical preparatives contqining them
WO2001075015A3 (en) A novel polypeptide, fat24 and the polynucleotide encoding the polypeptide
WO2001036979A3 (en) Placental human neurokinin b precursor
WO2001075039A3 (en) A novel polypeptide, human rna helicase 10 and the polynucleotide encoding the polypeptide
WO2001075061A3 (en) A novel polypeptide, cdv-1-42 and the polynucleotide encoding the polypeptide
WO2001083675A3 (en) A novel polypeptide, a atp-dependent human hydrolase serine 10.2 and the polynucleotide encoding the polypeptide
WO2001075006A3 (en) A novel poypeptide, light chain of protein lattice 37 and the polynucleotide encoding the polypeptide
WO2001075036A3 (en) A novel polypeptide, human immunophiline 14 and the polynucleotide encoding the polypeptide
WO2001075051A3 (en) A novel polypeptide, a human stroma antigen 3 protein 17 and the polynucleotide encoding the polypeptide
WO2001075016A3 (en) A novel polypeptide, a human tyrosinase 16, and the polynucleotide encoding the polypeptide
WO2001075042A3 (en) A novel polypeptide, atp-dependent human hydrolase serine 9 and the polynucleotide encoding the polypeptide
WO2002000831A3 (en) A novel polypeptide, a bromine group domain 12 and the polynucleotide encoding the polypeptide
WO2001075056A3 (en) A novel polypeptide, human light-chain clathrine 20 and the polynucleotide encoding the polypeptide
WO2001074128A3 (en) A novel polypeptide, microtubulin 11 and the polynucleotide encoding the polypeptide
WO2001079434A3 (en) A novel polypeptide, a human signal peptidase 10 and the polynucleotide encoding the polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001240020

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001914657

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2401652

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 564244

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001914657

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642